September 14, 2007 - Nucletron announced today the successful management buy-out from Delft Instruments, creating an independent company fully dedicated to radiation oncology, enabling Nucletron to more effectively deliver cancer treatment solutions globally.
The previous company, under Delft Instruments, was created in 1994 by merging Nucletron, the global leader in brachytherapy solutions, with the Oldelft Simulix brand of radiation therapy simulation and imaging technology. Additionally, in 2003, Nucletron integrated the Helax and Theratronics treatment planning and management solutions from MDS Nordion into its portfolio to create Oncentra MasterPlan and Oncentra Information Management.